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ABSTRACT  This study presents the results of research on DNA polymorphism in children with malignant brain 
tumors (172 patients, 183 in the control group). Genotyping was performed using an allele-specific tetraprimer 
reaction for the genes of the first (CYP1A1 (2 sites)) and second phases of xenobiotic detoxication (GSTM1, 
GSTT1, GSTP1, GSTM3), DNA repair genes XRCC1, XPD (2 sites), OGG1, as well as NOS1 and MTHFR. The in-
creased risk of disease is associated with a minor variant of CYP1A1 (606G) (p = 0.009; OR = 1.50) and a deletion 
variant of GSTT1, (p = 0.013, OR = 1.96). Maximum disease risk was observed in carriers of double deletions in 
GSTT1-GSTM1 (p = 0.017, OR = 2.42). The obtained results are discussed in reference to literary data on the risk 
of malignant brain tumor formation in children and adults.
KEYWORDS  gene polymorphism, malignant brain tumors in children, genes of xenobiotic detoxication, DNA 
repair genes.
INTRODUCTION
The causes behind the formation of malignant tumors 
of the central nervous system (CNS) in children, of 
which 80% are cerebral tumors, are unknown. Risk 
factors for this type of pathology include inherited 
susceptibility and the effects of irradiation. Several 
genetic syndromes, such as the Li-Fraumeni syn -
drome, Turcot syndrome, neurofibromatosis, and 
tuberous sclerosis, are known to cause CNS tumors. 
Moreover, there are families with an increased risk of 
cerebral tumor formation. For instance, a population 
cohort from Utah (USA) and a tumor register, which 
was created based on data from this cohort, indicate 
the importance of the inheritance factor in most com-
mon malignant diseases of the brain in adults (astro-
cytomas and glioblastomas) [1]. Studies of the Swed-
ish tumor register indicate that first-degree relatives 
are 2 to 3 times more likely to develop a brain tumor 
of the same histopathological type as their probands 
[2]. The offspring of people who had a brain tumor in 
their childhood are twice as likely to develop a similar 
tumor [3], the same being true for such a patient’s sib-
lings, especially before the age of 5. 
Relatives of patients with malignant diseases of the 
brain are also at risk of developing other oncological 
conditions. First-degree relatives of glioma patients 
have an increased standardized incidence ratio (SIR - 
ratio between the number of observed cases and the 
expected number) for developing any type of onco-
pathology (SIR = 1.21), especially before the age of 45 
(SIR = 5.08). Relatives of glioma patients most often 
develop brain tumors (SIR = 2.14), melanomas (SIR = 
2.02), and sarcomas (SIR = 3.83) [4].
Brain tumor incidence is now rising  in the major-
ity of highly developed countries, especially among 
children younger than 5 [5]. The role of environmen-
tal factors in childhood carcinogenesis, in general and 
in the CNS tumor development risk, is under investi-
gation. An association has been established between 
in utero ionizing radiation and the risk of developing 
leucosis and other tumors in childhood [6]. Another 
such association has been observed for women using 
diethylstilboestrol during pregnancy and the risk of 
their daughters developing clear-cell vaginal adeno-
carcinoma [7]. It has also been shown that brain tu -
mor development in offspring is often associated with 
parental occupational hazards, such as pesticides [8] 
or herbicides [9].  The association between maternal 
diets and the chance of their offspring developing 
brain tumors has also been researched. The most det-
rimental factors were found to be high amounts of ni-
trosamines, widely used for preserving meat and sau-
sage products, as well as large amounts of fat [10, 11]. 
Transplacental carcinogens of alkyl-nitroseureas are 
highly carcinogenic in relation to rat brain tumors [12]. 
Children with excessive [14] or insufficient [13] birth 
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weight, as well as children with an excessive head cir-
cumference (OR = 1.27 for every centimeter of excess 
after stratification of the cohort for sex, weight and 
height of the newborn) [15], and children whose moth-
ers have had miscarriages in their anamneses are also 
at higher risk of developing brain tumors [16]. Inten-
sive smoking (> 10 cigarettes a day) during pregnancy 
is also among the risk factors contributing to CNS tu-
mors in the offspring [13].
If hereditary syndromes associated with the risk of 
malignant tumor formation in the nervous system are 
absent, then genes with low penetrance take on the role 
of genetic risk factors [17]. Even though the structure of 
neuro-oncological disease incidence in adults and chil-
dren differs considerably [18, 19], it is the study of chil-
dren with sporadic tumors that allows for the effective 
identification of genetic susceptibilities, as compared 
to studies of adults. The higher the hereditary risk of 
cancer development, the easier it is for any environ-
mental factor of even the slightest risk to trigger tumor 
formation. 
Despite the fact that 20% of all the solid tumors in 
children are brain tumors, there have only been several 
associative studies of brain tumors on children from 
various ethnic populations. In a cohort of 73 children in 
Thailand with various types of CNS tumors it was dem-
onstrated an increased number of homozygous carriers 
of the minor variant of the MTHFR gene (polymor-
phism A1298C), which is involved in folate metabolism 
[20]. A study in the United States analyzed the distribu-
tion of xenobiotic detoxification gene alleles of GSTM1 
(insertion/deletion), GSTT1  (insertion/deletion), 
and GSTP1 (Ala114Val) genes among 173 child patients 
and registered the association of a functional allele of 
GSTM1 and a rare genotype of GSTP1 (Val114/Val114) 
with pediatric astrocytoma [21]. The same researchers 
showed that a combined cohort of adults (92) and chil-
dren (43) with brain tumors displayed a distribution of 
Arg72Pro genotype frequencies for the P53 gene that 
was considerably different from the control group. It 
has also been reported that highly malignant astrocy-
toma patient cohorts exhibit an increased number of 
Table 1. Studied genes and polymorphisms
Gene Latin name Polymorphism dbSNP assigned 
reference SNP ID Locus Gene functions
CytochromeP450 1А1 CYP1A1
T606G rs2606345
15q24.1
The 1-st phase of detoxifica-
tion - metabolic activation of 
the aromatic hydrocarbons  A4889G
Ile462Val rs1048943
Glutathione S-transferase 
mu 1  GSTM1 Insertion-
deletion - 1p13.3
The 2-nd phase of detoxifica-  2-nd phase of detoxifica- nd phase of detoxifica-  phase of detoxifica- phase of detoxifica-  of detoxifica- of detoxifica-  detoxifica- detoxifica-
tion – detoxification proper 
by conjugation of reduced 
glutathione to a wide number 
of exogenous and endogenous 
hydrophobic electrophiles 
Glutathione S-transferase 
theta 1  GSTT1 Insertion-
deletion - 22q11.2
Glutathione S-transferase 
mu 3 (brain)  GSTM3 G670A
V224I rs7483 1p13.3
Glutathione S-transferase 
pi 1  GSTP1 A313G
Ile105Val rs1695 11q13
X-ray repair, comple-
menting defective, in 
chinese hamster, 1
XRCC1 C589T 
Arg194Trp rs1799782 19q13.2 Base excision repair
Excision-repair, com-
plementing defective, in 
chinese hamster, 2
ERCC2
(XPD)
A2251C 
Lys751Gln rs13181
19q13.3 Nucleotide excision repair
G862A
Asp312Asn rs1799793
8-oxoguanine-DNA-
glycosylase OGG1 C977G
Ser326Cys rs1052133 3p26.2 Base excision repair - removal 
8-oxodeoxyguanosine
Nitric oxide synthase, 
neuronal
nNOS 
(NOS1) C276T rs2682826 12q24.2 NO production in neuronal 
tissues 
5,10-methylenetetrahy-
drofolate reductase MTHFR C677T
Ala222Val rs1801133 1p36.3
Conversion of 5,10-methylene-
tetra  hydrofolate to 
5-methyl  tetrahydrofolate, a 
cosubstrate for homocysteine 
remethylation to methionine 60 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
RESEARCH ARTICLES
heterozygous individuals for this P53 gene polymor-
phism [22]. 
Interaction of the environment and the genotype in 
relation to brain tumor incidence in childhood has been 
analyzed in two studies [23, 24]. In the case of exposure 
to phosphoorganic insecticides in utero or after birth, 
the increased risk of developing brain tumors is sig-
nificantly associated with a polymorphism of the PON1 
(C108T) detoxification gene, for which the above-said 
compounds are a substrate [23]. This study moved on 
to confirm the effects of PON1 on a larger cohort (201 
people) and also showed associations with the risk of 
brain tumor development for two other detoxifica-
tion genes involved in insecticide metabolism, FMO1 
(C9536A) and BCHE (A539T) [24].
This study presents the results of an associative 
study of genetic risk factors related to the formation 
of brain tumors in children. The choice of genotyping 
loci was based on literary data and on personal results 
obtained in a study of susceptibility genes that increase 
somatic mutability [25]. This study also includes genes 
which are primarily expressed in the brain (GSTM3 aka 
brain GSTM) and in neural tissues (NOS1, or  nNOS 
– neuronal) and which exhibit association with some 
oncological diseases [26, 27]. The involved loci are de-
scribed in Table 1.
EXPERIMENTAL PROCEDURES
A cohort of 172 children with malignant CNS tumors 
(92 boys and  80 girls) aged 2-16 were included in 
this study. These children were under treatment in 
the laboratory of the Children’s X-ray Radiology of 
the Russian Scientific Center of Roentgenoradiology 
from 2007 to 2010. The average age of the child pa -
tients was 8.96±0.38. The most common tumors in the 
studied cohort were medulloblastomas (N = 58) and 
brain stem tumors (N = 26). Apart from these, there 
were also cases of apoplastic ependymoma (N = 19), 
glioblastoma (N = 10), germinogenic tumors (N = 6), 
low malignancy astrocytoma (N = 5), high malignancy 
astrocytoma (N = 5), primitive neuroectodermal tu-
mors (N = 5), and others (N = 38). The control group 
consisted of 183 people (102 males and  81 females) 
aged 17 to 21, an average age of 19.90 ± 0.08 years. All 
the sick children and youths from the control group 
were of Caucasian race. The patient database contains 
information on their places of birth and residence. 
The children’s parents gave informed consent for the 
genotyping procedure. The ten-year difference in the 
average age of the patient and control groups could 
not have any significant effect on the allelic variant 
frequencies in the groups, since mortality in this age 
group does not exceed 0.1% (Table 2) [28]. Moreover, 
the first four main causes of death in the 15–24-age 
group are violence-related: unintentional bodily harm, 
suicide, undefined bodily harm and murder [29]. The 
criteria for involvement into the control group were 
age, nationality, birthplace inside the central regions 
of the European territory of the Russian Federation, 
and informed consent to the procedures. 
DNA was extracted from peripheral blood lym -
phocytes using a Diatom DNA Prep 200 kit, which uses 
guanidine isocyantate and Nucleus–sorbent (Isogen 
Laboratory, Russia). Genotyping was performed using 
allele-specific tetraprimer PCR [30]. This method al-
lows the amplification of DNA fragments of alternative 
alleles in a single test tube. The amplification products 
were separated using agarose gel electrophoresis and 
then stained with ethidium bromide. 
The statistical analysis was performed using stand-
ard methods available in the WinSTAT 2003.1 software 
integrated into Microsoft Excel. 
Estimation of the odds ratios (OR) and the significance 
of the odds ratio according to the precise Fischer test 
was accomplished using the free-use software WinPepi: 
http://www.brixtonhealth.com/pepi4windows.html. 
RESULTS
We identified the genotypes of the studied individu-
als at 12 polymorphic sites of 10 genes. The genotype 
frequencies in the control group and the patient group 
were in accordance with the Hardy-Weinberg distribu-
tion. 
Table 3 compares the frequencies of allele and geno-
type occurrence for 12 polymorphic sites in children 
with various tumors of the CNS, as well as youths in the 
control group. We also distinguished two major groups 
in the child patients cohort - a group with medulloblas-
toma and a group with brain stem tumors. 
In cases where the polymorphism was of an inser-
tion/deletion nature (genes GSTM1, GSTT1), we com-
pared two genotypes: “zero” – homozygous deletion 
(D/D) and “functional” – a genotype with a functional 
Table 2. Age-specific mortality in Russia in the 0-24-year 
age range
Age, 
years
Deaths per 1000 population
2006 2007 2008
0 10.2 9.4 8.5
1-4 0.7 0.6 0.6
5-9 0.4 0.3 0.3
10-14 0.4 0.4 0.3
15-19 1.1 1.1 1.1
20-24 2.2 2.1 1.9RESEARCH ARTICLES
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Table 3. Genotypes frequencies among the brain tumors patients and in the control group 
Loci, alleles, genotypes
Frequencies (%)
All brain tumors 
(N*=172)
Medulloblastoma  
(N*=63)
Brainstem tumor 
(N*=26) Healthy (N*=183)
CYP1A1 T606G
rs2606345
T 187 (54.68) 67 (53.18) 30 (57.69) 236 (64.48)
G 155 (45.32) 59 (46.83) 22 (42.31) 130 (35.52)
T/T 57 (33.33) 22 (34.92) 10 (38.46) 78 (42.62)
T/G 73 (42.69) 23 (36.51) 10 (38.46) 80 (43.72)
G/G 41 (23.98) 18 (28.57) 6 (23.08) 25 (13.66)
CYP1A1 A4889G
rs1048943
A 329 (95.64) 120 (95.24) 49 (94.23) 352 (96.18)
G 15 (4.36) 6 (4.76) 3 (5.77) 14 (3.83)
A/A 157 (91.28) 57 (90.48) 23 (88.46) 169 (92.35)
A/G 15 (8.72) 6 (9.52) 3 (11.54) 14 (7.65)
G/G 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
GSTM1
D/D 93 (54.07) 35 (55.56) 16 (61.54) 95 (51.91)
I/* 79 (45.93) 28 (44.44) 10 (38.46) 88 (48.09)
GSTT1
D/D 45 (26.16) 20 (31.75) 9 (34.62) 28 (15.30)
I/I* 127 (73.84) 43 (68.25) 17 (65.38) 155 (84.70)
GSTP1
A313G
rs1695
A 242 (70.35) 87 (69.05) 31 (62.00) 247 (67.49)
G 102 (29.65) 39 (30.95) 19 (38.00) 119 (32.51)
A/A 80 (46.51) 29 (46.03) 8 (32.00) 79 (43.17)
A/G 82 (47.67) 29 (46.03) 15 (60.00) 89 (48.63)
G/G 10 (5.81) 5 (7.94) 2 (8.00) 15 (8.20)
GSTM3 
G670A
rs 7483
G 203 (59.01) 80 (63.49) 28 (53.85) 222 (60.66)
A 141 (40.99) 46 (36.51) 24 (46.15) 144 (39.34)
G/G 63 (36.63) 26 (41.27) 8 (30.77) 73 (39.89)
G/A 77 (44.77) 28 (44.44) 12 (46.15) 76 (41.53)
A/A 32 (18.60) 9 (14.29) 6 (23.08) 34 (18.58)
NOS1 
C276T
rs 2682826
C 243 (70.64) 90 (71.43) 33 (63.46) 271 (75.70)
T 101 (29.36) 36 (28.57) 19 (36.54) 87 (24.30)
C/C 84 (48.84) 33 (52.38) 9 (34.62) 103 (57.54)
C/T 75 (43.60) 24 (38.10) 15 (57.69) 65 (36.31)
T/T 13 (7.56) 6 (9.52) 2 (7.69) 11 (6.15)
MTHFR
 C677T
rs1801133
C 228 (70.81) 76 (66.67) 36 (72.00) 221 (67.79)
T 94 (29.19) 38 (33.33) 14 (28.00) 105 (32.21)
C/C 80 (49.69) 25 (43.86) 13 (52.00) 70 (42.94)
C/T 68 (42.24) 26 (45.61) 10 (40.00) 81 (49.69)
T/T 13 (8.07) 6 (10.53) 2 (8.00) 12 (7.36)
XRCC1 
C589T
rs 1799782
C 322 (93.61) 119 (94.44) 46 (88.46) 337 (94.13)
T 22 (6.40) 7 (5.56) 6 (11.54) 21 (5.87)
C/C 150 (87.21) 56 (88.89) 20 (76.92) 160 (89.39)
C/T 22 (12.79) 7 (11.11) 6 (23.08) 17 (9.50)
T/T 0 (0.00) 0 (0.00) 0 (0.00) 2 (1.12)
XPD
T2251G
rs 13181
T 212 (61.63) 82 (65.08) 32 (61.54) 248 (68.13)
G 132 (38.37) 44 (34.92) 20 (38.46) 116 (31.87)
T/T 63 (36.63) 25 (39.68) 9 (34.62) 84 (46.15)
T/G 86 (50.00) 32 (50.79) 14 (53.85) 80 (43.96)
G/G 23 (13.37) 6 (9.52) 3 (11.54) 18 (9.89)
XPD
G862A
rs1799793
G 211 (61.70) 82 (66.13) 32 (61.54) 242 (66.48)
A 131 (38.30) 42 (33.87) 20 (38.46) 122 (33.52)
G/G 64 (37.43) 26 (41.94) 9 (34.62) 80 (43.96)
G/A 83 (48.54) 30 (48.39) 13 (50.00) 82 (45.05)
A/A 24 (14.04) 6 (9.68) 4 (15.38) 20 (10.99)
OGG1
C977G
rs1052133
C 274 (80.59) 92 (77.97) 40 (76.92) 270 (78.04)
G 66 (19.41) 26 (22.03) 12 (23.08) 76 (21.97)
C/C 116 (68.24) 36 (61.02) 18 (69.23) 105 (60.69)
C/G 42 (24.71) 20 (33.90) 4 (15.38) 60 (34.68)
G/G 12 (7.06) 3 (5.08) 4 (15.38) 8 (4.62)
*The number of individuals genotyped at certain loci may differ.
Note. Genotypes associated with diseases are highlighted in grey. 62 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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allele in either homo- or heterozygous form (I/∗). Hence 
and further ∗ depicts an unspecified allele.
Increased susceptibility to brain tumor development 
was observed for carriers of the D/D genotype of the 
GSTT1 gene. A two-side Fischer test for all the CNS 
tumor types yields p = 0.013, OR = 1.96, 95% confidence 
interval 1.16–3.32; for medulloblastoma patients - 
p = 0.009, OR = 2.57, 95% confidence interval 1.33–4.99; 
for children with brain stem tumors - p = 0.026, OR = 
2.93, 95% confidence interval 1.21–7.12. Of all the ana-
lyzed two-loci combinations, the one associated with 
the highest risk of malignant brain tumors turned out 
to be a double deletion of GSTM1-GSTT1 (27 people 
– 15.7% patients; p = 0.017, OR = 2.42, 95% confidence 
interval 1.18–4.95) (Figure). 
The risk of developing any type of brain tumor, and 
specifically a medulloblastoma, turned out to be up in 
carriers of the minor 606G allele of the CYP1A1 gene 
(for all types of tumor - p = 0.009, according to the two-
sided Fischer test, OR= 1.50, 95% confidence interval 
1.11–2.03, for medulloblastoma - p = 0.026, OR = 1.60, 
95% confidence interval 1.06–2.41). 
Among the brain stem tumor patients there was an 
elevated number of NOS1*276T minor allele carriers in 
both homo- and heterozygous forms, where p = 0.035, 
OR = 2.56, 95% confidence interval 1.10–5.96. The whole 
patient group also exhibited an increased occurrence of 
the minor allele; however, these data were statistically 
insignificant - p = 0.11, OR = 1.42, 95% confidence in-
terval 0.93–2.16. 
There was also a tendency for association between 
the 2251G minor allele of the nucleotide excision DNA 
repair gene XPD in both homo- and heterozygous 
forms and an increased chance of developing a brain 
tumor (p = 0.084, OR = 1.48, 95% confidence interval 
0.97–2.27).
DISCUSSION
The detoxification of xenobiotics consists of two main 
stages of detoxification and a third stage - secretion of 
the detoxified products out of the cell. The first stage 
involves activation of the xenobiotic compounds by 
P-450 cytochromes and a number of other enzymes. 
The second stage is the detoxification, per se, and it in-
volves glutathione-S-transferases and other proteins. 
The intermediary electrophilic metabolites that were 
formed in the first stage are toxic, and effective detoxi-
fication requires a fine balance between the activity 
of the first- and second-stage enzymes. This balance is 
deregulated both by insufficient activity of the poly-
morphic variants of the second-stage enzymes and by 
the increased activity of the first-stage enzymes [31]. 
Increased activity of the first-stage detoxification en-
zymes and insufficient activity of the second-stage en-
zymes (GST) cause an increase in the level of activated 
electrophilic metabolites, thus increasing the deleteri-
ous effects of the xenobiotic compounds. 
This study demonstrates that there is an association 
between certain xenobiotic detoxification gene alleles 
and the development of brain tumors in children. The 
risk of developing malignant tumors in the brain dur-
ing childhood is increased in carriers of a minor variant 
of CYP1A1 (606G). 
The role of CYP1A1 polymorphism has not been 
studied in relation to child neurooncology. Associa-
tive studies on adults have shown no association be-
tween CYP1A1 A4889G (Ile462Val) polymorphism and 
the risk of developing glioma or several other types of 
malignant brain tumors [32–34]. The CYP1A1 gene is 
located in the 15q22-24 region, and people with a he-
reditary predisposition towards glioma have exhibited 
associations between the disease and low-penetrance 
markers in the 15q23-q26.3 region which overlaps this 
locus [35].
Data on the role of CYP1A1 gene polymorphism in 
carcinogenesis are contradictory, and it seems that 
their role considerably depends on the interaction be-
tween the genotype and the environment [36]. The 
T606G site is located in the first intron of the CYP1A1 
locus. The single nucleotide substitutions (SNP) locat-
ed in the intron regions do not usually influence gene 
activity. However, the T606G polymorphism has been 
associated with lung cancer [37], hormone-dependent 
tumors [38], and with the level of sex hormones, which 
are substrates of CYP1A1 [39]. There are data on the 
T606G site which indicate that in the absence of spe-
cific substrates, the allelic 606T (SNP T606G) vari-
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ant of the CYP1A1 gene is expressed more actively, 
whereas the 606G variant is induced in the presence of 
specific substrates (polycyclic aromatic hydrocarbons 
of exogenous origins, such as foods, industrial waste, 
tobacco smoke, as well as endogenous compounds, 
such as estrogens). The differential effect of the allelic 
variants 606G and 606T on the observed effects under 
ecologically unfavorable conditions (industrial pollu-
tion of air, smoking), as well as in their absence, has 
been demonstrated in two independent studies [40, 41]. 
The two studied sites in the CYP1A1 locus which were 
studied in this work are in strong linkage disequilib-
rium - D’=0.913, r=0.229, p=0, and the minor alleles 
(4889G, 606G) belong to a single linkage group. Linkage 
disequilibrium data in the patient and control groups 
were identical. In this work, we have confirmed our 
previous data obtained on different cohorts and indi-
cating that the polymorphic sites A4889G and T606G 
are linked [25, 42]. According to data from HapMap, the 
frequency of the 606G allele in Caucasians is 0.36–0.45, 
while the frequency of 4889G is 0.04–0.07. Until re-
cently, researchers had studied three major polymor-
phic sites in the CYP1A1 gene in European populations: 
T3801C, A4889G, and C4887A [43]. Besides, polymor- 3801C, A4889G, and C4887A [43]. Besides, polymor- C, A4889G, and C4887A [43]. Besides, polymor- , A4889G, and C4887A [43]. Besides, polymor- A4889G, and C4887A [43]. Besides, polymor- 4889G, and C4887A [43]. Besides, polymor- G, and C4887A [43]. Besides, polymor-  and C4887A [43]. Besides, polymor- C4887A [43]. Besides, polymor- 4887A [43]. Besides, polymor- A [43]. Besides, polymor-  [43]. Besides, polymor-
phism T606G has a functional character, the frequency 
of the 606G allele is higher than the frequency of the 
minor alleles at other polymorphic sites. Thus, this al-
lele seems to be a new promising marker for associative 
studies of multifactor diseases.
Our study also shows associations between the for-
mation of malignant brain tumors and the possession of 
deletion variants of GSTT1 (D/D) (OR=1.96, p= 0.013). 
Association between polymorphism of glutathione-S-
transferase genes, which encode enzymes for the sec-
ond phase of xenobiotic detoxification, and the develop-
ment of brain tumors in children, was analyzed in study 
[21]. Statistically significant results were obtained for 
the functional allele of GSTM1 and a minor allele of 
GSTP1 313G. Association between the development of 
malignant brain tumors in adults and polymorphisms 
of glutathione-S-transferase-encoding genes was ana-
lyzed much more thoroughly; for instance, 10 studies 
were conducted in Europe [32–34, 44–50]. The results 
of seven of these studies and the results of the afore-
mentioned work on a cohort of sick children [21] were 
combined in a meta-analysis [51], which was performed 
for two of the most common nosological forms: gliomas 
and meningiomas. According to this meta-analysis, in 
Caucasians the deletion variant of GSTT1 occurred sig-
nificantly more often in meningioma patients (OR = 
1.95). No differences in the frequencies of the GSTM1 
(Ins/Del) and GSTP1 A313G (Ile105Val) and the adja-
cent C341T (Ala114Val) allele were observed between 
the patient and control groups. Another large-scale 
study obtained data indicating the absence of an as-
sociation between polymorphisms of  GSTM1 (Ins/
Del), GSTM3 (A63С), GSTT1 (Ins/Del) and the devel-
opment of gliomas, glioblastomas, and meningiomas. 
It was demonstrated that the 105G-114C (Val-Ala) 
haplotype of GSTP1 has a weak protective effect on 
the chance of developing glioma [32].
No significant differences in DNA repair gene allele 
frequencies were found (Table 3); however, there was 
a tendency level association of the minor 2251G allele 
in the XPD locus with an elevated chance of developing 
the disease. 
Associative studies of malignant tumors of any lo-
calization concerning DNA repair gene polymorphisms 
most often involve XPD nucleotide excision repair 
genes and XRCC1 base excision repair genes [52], 
which are located on the same region of the chromo-
some (19q13.2–3). Most of the results of associative 
studies of brain tumors are summarized in review [53]. 
It was shown that in adults, the most common malig-
nant tumors of neuroepithelial tissues are associated 
with the nucleotide excision repair genes XPD, ERCC1 
and a gene located in the same (19q13.2-3) region of 
the chromosome - GLTSCR1 (glioma tumor suppres-
sor candidate of an unknown function) [54]. Caggana et 
al. [55] showed that of 7 polymorphic sites in the XPD 
gene, maximum association with an increased risk of 
glioma was observed for the least studied synonymous 
Arg156Arg polymorphism, which may be a marker 
of another unknown gene that predisposes potential 
patients to this disease. Sites T2251G (Lys751Gln) 
and G862A (Asp312Asn) of the XPD gene are located 
12340 b.p. apart and are linked. This work has obtained 
the following linkage disequilibrium data: D’=0.674, 
r=0.662, p=0 (no difference between the patient and 
control groups), which is in agreement with the pub-
lished data on Caucasians [56]. Despite the absence of 
significant results concerning DNA repair genes in this 
work, studying polymorphic loci in the 19q13.2-3 chro-
mosome region seems a promising line of research that 
could lead to the discovery of risk markers for malig-
nant brain tumors in children. 
This study also shows that a minor allele of the neu-
ronal nitric oxide synthase occurs significantly more 
often in patients with brain stem tumors (Table 3); dif-
ferences for the whole patient group are statistically 
insignificant. 
Genes from the nitric oxide synthase family, which 
includes the neuronal nitric oxide synthase gene, are 
usually studied in connection with inflammatory proc-
esses. However, nNOS polymorphism is associated with 
melanoma predisposition [27]. Melanoma is included 
into the nerve-ending tumor group. Families that have 
a hereditary predisposition towards brain tumors are 64 | ACTA NATURAE |  VOL. 2  № 4 (7)  2010
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often predisposed towards developing melanomas as 
well [5]. Taking into account the elevated expression of 
nNOS in nervous tissue, as well as the putative cross-
sensitivity to melanoma and glioma, we resolved to an-
alyze the C276T site of the nNOS gene. This polymor-
phism is considered to be functional, since the single 
nucleotide substitution in the untranslated region re-
sults in elevated mRNA expression of the minor variant 
[57]. Significant results on the association of the minor 
allele with increased risk of developing brain tumors 
were only observed for the small group of patients with 
brain stem tumors and will of course require further 
study.
Our previous associative studies of xenobiotic de-
toxification genes have shown that women with repro-
ductive system diseases (mainly myomas and chronic 
cystic mastitis) carrying the 606G, 4889G alleles of 
the CYP1A1 gene have an increased frequency of so-
matic mutations at the T-cell receptor (TCR) locus in 
peripheral blood lymphocytes (phentoype CD3-CD4+). 
It is known that the number of such TCR-mutant lym-
phocytes is elevated in cancer patients (cancer of the 
larynx and hypopharynx, thyroid gland tumor, cervical 
cancer and Hodgkin’s lymphoma) and in people with 
hereditary predispositions towards oncological diseases 
(ataxia-teleangiectosia) [58, 59]. The single direction of 
the effects in two separate studies may indicate the 
pleiotropic effect of detoxification genes, which leads to 
insufficient resistance of the organism in the genotype-
environment interaction process. Besides the possible 
increased risk of disease due to altered detoxification 
enzyme activity, allelic variants associated with somatic 
mutability and with predisposition to the formation of 
malignant tumors in childhood may act as markers of a 
linked group of unknown genes that can be responsible 
for some of the observed effects. The obtained results, 
if confirmed by independent studies, can be useful for 
identifying the genetic risk factors involved in the for-
mation of malignant tumors in children.  
This work was supported under the Biological Variety 
RAS Presidium program for basic research, under the 
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